PCA
IHE icon

Pallas Capital Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Pallas Capital Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-58,258
Closed -$3.83M – 784
2024
Q4 		$3.83M Buy
+58,258
New +$4.01M 0.16% 112

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pallas Capital Advisors's IHE Position: Q1 2025 in Review

Pallas Capital Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2025, closing a stake of 58,258 shares — an estimated $3.83M sold.

Pallas Capital Advisors first reported a position in IHE in Q4 2024 and held it in 1 quarter. The position peaked at $3.83M in Q4 2024. 149 funds tracked by Wall St. Rank hold IHE as of Q1 2025.

  • Pallas Capital Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 58,258 iShares US Pharmaceuticals ETF shares in Q1 2025, an estimated $3.83M.
  • Pallas Capital Advisors first reported a position in iShares US Pharmaceuticals ETF in Q4 2024 and held it in 1 quarter.
  • Pallas Capital Advisors's iShares US Pharmaceuticals ETF position peaked at $3.83M in Q4 2024.
  • 149 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2025.

Based on Pallas Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.